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Abstract 
Background: Maffucci syndrome is characterized by the sporadic occurrence of multiple enchondromas together 
with multiple hemangiomas. Patients with Maffucci syndrome are at increased risk of developing different kinds of 
malignant tumors.
Case presentation: We report on a 39-year-old woman who was diagnosed with Maffucci syndrome together with 
intrahepatic cholangiocarcinoma (IHCC). Heterozygous somatic mutations in the isocitrate dehydrogenase 1 and 2 
(IDH1/IDH2) genes are associated with a number of different tumor types (e.g. IHCC) and also with Maffucci syndrome. 
For IHCC, mutations in IDH1/IDH2 are associated with higher survival rates. IHCC tissue as well as normal liver tissue 
and peripheral blood were analyzed for IDH1/IDH2-mutations in our patient. In the tumor sample, we identified a 
recurrent somatic IDH1-mutation affecting Arg132, while in normal liver tissue and peripheral blood, no variants were 
detected, as expected.
Conclusion: This case report presents the second patient in the literature exhibiting the features of Maffucci syn-
drome along with cholangiocarcinoma. This supports the hypothesis that IDH1/2-mutations, which can be present in 
different types of tumor tissue simultaneously, arise during embryonic development in a mosaic pattern; as a result, a 
more aggressive follow-up is proposed in patients with Maffucci syndrome to exclude neoplasms.
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Background
Maffucci syndrome (also known as dyschondrodysplasia 
with hemangiomas, enchondromatosis with multiple cav-
ernous hemangiomas, Kast syndrome, hemangiomatosis 
chondrodystrophica, and enchondromatosis Spranger 
type II) was first described in 1881. It is a rare disease, 
with fewer than 200 cases having been reported world-
wide to date. Maffucci syndrome is characterized by 
the presence of multiple enchondromas combined with 
multiple soft tissue hemangiomas or lymphangiomas 
[1]. There is a tendency for malignant transformation 
of enchondromas into chondrosarcomas or of heman-
giomas into vascular sarcomas. Patients with Maffucci 
syndrome also are susceptible to the development of 
other malignant lesions such as glioma (summarized in 
Table 1).
Somatic mutations in the isocitrate dehydrogenase 1 
(IDH1) or IDH2 genes are common in enchondromas 
and chondrosarcomas, as well as in several neoplasms, 
including glioma, glioblastoma, acute myeloid leukemia, 
and intrahepatic cholangiocarcinomas (IHCC) [2–4].
Case presentation
A 39-year-old woman was referred to the department of 
surgery because of a large tumor in her right hepatic lobe. 
The liver node was found incidentally at sonography. The 
patient did not complain of any abdominal problems.
The patient’s medical history reported that at the 
age of 7  years, she had been diagnosed with two nodes 
on the heel suspicious of hemangiomas, and at the age 
of 16  years she developed diffuse nodes suspicious of 
hemangiomas. One subcutaneous hemangioma in the 
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upper lumbar region had been surgically removed and 
histologically confirmed in 2000. From 2003, she had 
a history of multiple enchondromas on her right fibula, 
ribs and clavicle, and the diagnosis of Maffucci syndrome 
was therefore proposed. As an inhabitant of Kyiv, the 
patient had been exposed to radiation from Chernobyl as 
a child.
Computer tomography (Fig.  1a) showed a mass in 
the right hepatic lobe measuring 9  cm in the larg-
est dimension. Whereas ultrasound-guided biopsy did 
not achieve a definitive histological diagnosis (cytol-
ogy showed suspicious cells), the tumor was highly sug-
gestive of a neoplasm on computed tomography (CT) 
and magnetic resonance imaging (MRI). A failure to 
enhance on gadoxetic acid (primovist)-enhanced MRI 
(Fig. 1b) excluded adenoma and focal nodular hyperpla-
sia (FNH). Primary staging, including gastroscopy and 
colonoscopy, did not reveal any other tumor sites. The 
preoperative differential diagnosis was primarily between 
hepatocellular carcinoma and sarcoma. Resection was 
recommended by our multidisciplinary tumor board. 
The patient underwent right extended hemihepatectomy 
(V +  VI +  VII +  VIII +  IVa segments) with cholecys-
tectomy. Additionally, two subcutaneous hemangiomas 
were removed from the abdominal wall.
Methods
Pathology
Representative areas from the right hepatectomy speci-
men were sampled, and 5-μm sections from the forma-
lin-fixed, paraffin-embedded tissue were used for routine 
light microscopic analysis, as well as immunohistological 
analysis. The antibodies used for immunohistology were 
HepPar, Synaptophysin, Chromogranin A, ERG, CKpan, 
Table 1 Description of Maffucci patients with or without neoplasms worldwide













Follow-up Year of  
publication
References
1 1 probably malignant  
transformation of a  
clavicular lesion
0 No 1881 [11]




7 4 (three of them had  
two neoplasms each)
3 BC, PC, astrocytoma Yes 1987 [8]
1 0 1 Astrocytoma 1987 [13]
1 0 1 Astrocytoma 1990 [14]
1 0 1 Ovarian fibrosarcoma No 1990 [15]
1 0 1 Astrocytoma 1991 [16]
1 0 0 No 2001 [17]
17 9/17 (53 %) 0 Yes 2011 [10]
1 1 1 Hemangioendothelioma Yes 2012 [18]
1 1 0 No 2012 [19]
1 0 1 Spindle cell hemangioma No 2013 [20]
1 1 0 No 2013 [11]
1 0 0 No 2013 [21]
1 0 1 Anaplastic astrocytoma No 2014 [22]
1 1 0 No 2014 [23]
1 0 0 No 2014 [24]
1 1 0 No 2014 [25]
1 1 0 No 2014 [26]
9 1 1 Acute myeloid leukemia 
and von Willebrand 
disease
No 2014 [27]
1 1 0 No 2015 [28]
1 1 0 No 2015 [29]
1 1 0 No 2015 [30]
1 0 0 No 2015 [31]
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Fig. 1 Preoperative imaging studies. a Computed tomography of liver tumor showed a 9 cm mass in the right lobe of liver; b Gadoxetic acid 
(primovist)-enhanced MRI demonstrated a lesion in liver segments VII and VIII, peripherally hypointense compared to surrounding liver in T2w, 
centrally hyperintense. A strong arterial hypervascular enhancement was demonstrated after primovist administration and there was a failure to 
enhance in the hepatobiliary phase. The tumor has contact with the inferior vena cava and some mm distance from middle liver vein. T1 fat satu-
rated post gadoxetic acid. Hepatobiiliary phase (20 min post injection). c Soft tissue hemangioma (MRI). Hemangioma dorsal to upper ankle joint, 
PDw fat saturation (proton density weighted, fat saturated MRI)
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S-100, CK7, CK20, CDX 2, CEA, CA19.9, PAX8, ER, PR, 
and CA12.5.
Histopathologic findings
The right hemihepatectomy tissue had a weight of 725 g 
and dimensions of 21 × 12 × 7.5 cm. The tissue included 
part of the diaphragm 4  ×  2  cm from the cranial side. 
The tumor was multinodular and 8.5 × 6.5 × 6 cm in size 
(Fig. 2). Histologically, it was liver tissue with infiltration 
of tubular to partially solidly growing adenocarcinoma, 
with middle proliferative activity and a focal hepatocellu-
lar component, which was a maximum of 8.5 cm. Immu-
nohistochemical staining of neoplastic cells showed 
strong staining with cytokeratin 7 (CK7) and CPpan 
(Fig. 3), and weaker staining with cytokeratin 20 (CK20). 
Some tumor cells displayed weak staining for HepPar1 
(Fig. 3). The tumor cells were negative for synaptophysin, 
chromogranin A, Ets-related gene (ERG), S-100, CDX 2, 
carcinoembryonic antigen (CEA), CA19.9, PAX8, estro-
gen receptor, progesterone receptors, cytokeratin 19 
(CK19), CA19.9, GATA 3, and alpha-fetoprotein (AFP), 
as well as for CA12.5. There was a focal intracytoplasmic 
positivity in PAS-staining (Fig. 3). The proliferation rate, 
visualized with MIB1, was seen in hot spots, up to 10 %.
The adjacent non-tumorous liver tissue did not reveal 
any significant histopathological abnormality. The final 
diagnosis was stage I peripheral intrahepatic cholangio-
carcinoma pT1, R0, G2.
In addition, two subcutaneous nodes were removed 
from the abdominal wall. Histologically, both of them 
were partially thrombosed capillary hemangiomas 
(Fig. 4).
Genetics
DNA was extracted from paraffin-embedded tumor tis-
sue, from paraffin-embedded normal liver tissue and 
from peripheral blood. We analyzed the 10 coding exons 
of the IDH1 gene by Sanger sequencing and detected 
the mutation c.394C  >  T (p.Arg132Cys) in exon 4 of 
IDH1 in the heterozygous state. This mutation leading to 
the amino acid change from arginine at position 132 to 
cysteine is a recurrent one and is found in the majority of 
the analyzed IDH1-positive tumor tissues [5]. In order to 
complete the genetic analysis, we subsequently Sanger-
sequenced the IDH2 gene with no remarkable results.
Biochemically, mutations in IDH1/IDH2 impair the 
substrate affinity of the enzyme and dominantly inhibit 
wildtype IDH1 activity through the formation of catalyti-
cally inactive heterodimers [6].
Heterozygous somatic mutations in isocitrate dehydro-
genase 1 and 2 (IDH1/IDH2) are key events in the devel-
opment of different kinds of malignant tumors, such as 
glioma, acute myeloid leukemia and intrahepatic cholan-
giocarcinoma (IHCC) [5]. They are also associated with 
Maffucci syndrome: over 80 % of patients with Maffucci 
syndrome carry somatic mutations in IDH1/IDH2 [3], 
while IDH1/IDH2 mutations are detected in 14 % of non-
syndromic cases with IHCC [7].
Discussion and conclusion
Patients with Maffucci syndrome can develop both skele-
tal and non-skeletal malignant lesions such as glioma [8]. 
As enchondromas and gliomas of Maffucci patients carry 
IDH1/IDH2 mutations while wild-type IDH1/IDH2 is 
expressed in their healthy tissue it is concluded that hete-
rozygous IDH1/IDH2 mutations occur during embryonic 
development, leading to mosaicism and acting as triggers 
of carcinogenesis [5].
Our case strengthens this hypothesis due to the pres-
ence of a somatic IDH1-mutation in the IHCC tumor tis-
sue of a patient with Maffucci syndrome. The presence of 
the mutation in enchondroma/hemangioma tissue of the 
patient remains to be confirmed.
The coexistence of Maffucci syndrome with cholan-
giocarcinoma is rare. To our knowledge, this case is the 
second to be reported. The first case was described in 
1987. The female patient with Maffucci syndrome devel-
oped a chondrosarcoma of the femur at the age of 32 and 
a biliary adenocarcinoma at the age of 44, which she died 
from [8].
Our patient was exposed to the Chernobyl fall-out at 
the age of 11. It has been demonstrated that three types 
of liver cancer (hemangiosarcoma, cholangiocarcinoma 
and hepatocellular carcinoma) are significantly associ-
ated with chronic exposure to high LET α-particle radia-
tion [9]. However, considering the clinical and genetic 
findings, this exposure to nuclear radiation did not 
appear to play a major role in this case.
Fig. 2 Pathological findings. Right hemihepatectomy tissue
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Fig. 3 Histology and immunhistology of cholangocarcinoma
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For IHCC cases, mutations in IDH1/IDH2 are associ-
ated with prolonged survival. The probability of tumor 
recurrence in patients with mutated IDH1/IDH2 intra-
hepatic cholangiocarcinoma is significantly lower than in 
those with wild-type IDH1/IDH2 (45 and 81  %, respec-
tively, for a 7 year interval) [7]. So far, the reason for this 
difference is not fully understood.
An important question concerns the monitoring of 
patients with Maffucci syndrome for the early detection 
of malignancies. In order to identify chondrosarcomas, 
Vedegaal and co-workers proposed technetium scans 
in patients with more than one enchondroma. X-rays of 
every single enchondroma have been recommended to 
provide a baseline for future comparison [10]. To iden-
tify non-skeletal neoplasms, some authors have advo-
cated a cerebral or abdominal CT when neurological or 
abdominal symptoms appear [10]. Our patient clearly 
demonstrates that the moment of clinical manifestation 
may be too late for successful management. In this case, 
an incidental sonography detected the IHCC, which is an 
aggressive neoplasm with an overall 5-year survival rate 
of 25–35  % after surgical treatment. For follow-up, we 
recommended a whole body MRI annually in addition to 
the usual oncological care. Future studies should aim to 
establish appropriate monitoring for patients with Maf-
fucci syndrome to detect malignancies early.
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